Order Article Reprints

Muñoz-Mármol AM, Meléndez B, Hernandez A, Sanz C, Domenech M, Arpí-Llucia O, Gut M, Esteve A, Esteve-Codina A, Parra G, et al. Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib. Cancers. 2025; 17(3):375. https://doi.org/10.3390/cancers17030375

Muñoz-Mármol, Ana Maria, Bárbara Meléndez, Ainhoa Hernandez, Carolina Sanz, Marta Domenech, Oriol Arpí-Llucia, Marta Gut, Anna Esteve, Anna Esteve-Codina, Genis Parra, and et al. 2025. "Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib" Cancers 17, no. 3: 375. https://doi.org/10.3390/cancers17030375

Muñoz-Mármol, A. M., Meléndez, B., Hernandez, A., Sanz, C., Domenech, M., Arpí-Llucia, O., Gut, M., Esteve, A., Esteve-Codina, A., Parra, G., Carrato, C., Aldecoa, I., Mallo, M., Pineda, E., Alameda, F., de la Iglesia, N., Martinez-Balibrea, E., Martinez-Cardús, A., Estival-Gonzalez, A., & Balana, C. (2025). Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib. Cancers, 17(3), 375. https://doi.org/10.3390/cancers17030375